The global dried blood spot collection cards market size was USD 350.7 Mn in 2022 and is likely to reach USD 517.84 Mn by 2031, expanding at a CAGR of 4.45% during 2023–2031. The market growth is attributed to the increase in forensic toxicology applications as well as the rise in the use of dried blood spot cards in diagnostics.
The dried blood spot (DBS) collection is a screening technique used to test the blood sample for diagnosis of chronic illness and infectious diseases such as hepatitis and autoimmune disorders. The technique is primarily designed to detect antibodies, which are agents that fight against HIV, HCV, HBV, and other diseases.
The test is performed by collecting a blood drop of a patient from his/her finger, toe, or heel and transferring the blood to a filter paper, and making it dried to form a dried blood spot. This technique is minimally invasive. These prepared samples are then transported to an analytical or clinical laboratory for conducting various examinations under ambient conditions.
Dried Blood Spot cards are widely applied in various fields such as drug discovery and drug development, forensic science, systems biology, biomarker development and biomarker validation, and others. Some of the major clinical applications of DBS include therapeutic drug monitoring, HIV surveillance, newborn screening (NBS), and clinical chemistry.
The wide and common clinical use of DBS is in newborn screening programs, which work on the detection of metabolic disorders. The Wolf Administration and The Government of Pennsylvania stressed the significance of NBS programs as it is vital for early diagnosis in infants.
As a result, in November 2018, the government bodies established to make these tests mandatory for early identification of serious disorders such as sickle cell anemia, congenital hypothyroidism, congenital adrenal hyperplasia, phenylketonuria, classic galactosemia, glycogen storage disease type II (Pompe Disease), maple syrup urine disease (MSUD), and X-linked Adrenoleukodystrophy.
DBS cards also play a vital role in serological diagnostics of infectious or autoimmune diseases. As per World Health Organization (WHO), in 2018 nearly 38 million people were diagnosed with HIV globally as well as around 770,000 HIV-related deaths were documented worldwide in the same year.
As DBS provides early and accurate results of the diagnosis of HIV most nations around the globe have started to use DBS for HIV diagnosis. For example, in 2016 the New South Wales (NSW) Ministry of Health launched the DBS HIV Testing Project for HIV testing. With the help of DBS technology, the NSW HIV Strategy 2016-2020 aimed at eliminating HIV by 2020.
The market report finds that the COVID-19 pandemic has shown a positive impact on the market as several DBS technology is widely used for coronavirus detection globally, which proved to be advantageous as it provided early and precise detections. The wide prevalence of COVID-19 cases, the expansion of the screening process through DBS cards for metabolic disorders, and its wide applicability in diagnosing diseases are boosting the market.
Dried Blood Spot Collection Cards Market Dynamics
The global dried blood spot collection cards market report has up-to-date insights that help in formulating a strategic roadmap about the estimated market scenario and performance during 2023 to 2031.
Drivers
Increasing demand for newborn screening is expected to drive the growth of the market. A dried blood spot cards is used for a specific group of conditions and the small pieces of DBS are pressed out and used to perform as the newborn screen. DBS is useful for studying birth defects and diseases.
However, the increasing use of DBS in the detection of autoimmune disorders and infectious diseases is projected to propel the market growth in the coming years. DBS technology is a better alternative to plasma-based testing and offers easy collection and storage along with less laboratory capacity, which are key factors driving the market growth.
Restraints
Rising requirements for large sampling tests contamination and spot inhomogeneity are major challenges that hamper the growth of the market. Contamination of filter paper samples has a substantial effect on the newborn screening results restraining the market growth. Factors that affect DBS testing and bioanalysis include the selection of type or card, the effect of spotting with capillary, and the optimization of extraction.
Opportunities
Increasing technologically advanced products and new launches are expected to create lucrative opportunities for the market players. GenTegra introduced a new Ahlstrom Gensaver 2.0 Forensic Card, that provides substantially high yields of DNA than the FTA Classic card. GenTegra 2.0 card is a choice for all sample collections including forensic sample collections.
Scope of Dried Blood Spot Collection Cards Market Report
The global dried blood spot collection cards market research report includes an assessment of the market trends, market segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Dried Blood Spot Collection Cards Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2020–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Application (Infectious Disease Testing, Newborn Screening, Therapeutic Drug Monitoring, Forensics, and Others), and Type (Whatman 903, Ahlstrom 226, FTA, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Dried Blood Spot Collection Cards Market Size and Analysis, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Ahlstrom; QIAGEN; PerkinElmer Inc.; F. Hoffmann-La Roche Ltd; CENTOGENE N.V.; Shimadzu Scientific Instruments.; Eastern Business Forms, Inc; Pall Corporation.; ARCHIMED Life Science GmbH; and Hemaxis
|
Dried Blood Spot Collection Cards Market Segment Insights
Based on application, the dried blood spot collection cards market is categorized into infectious disease testing, newborn screening, therapeutic drug monitoring, forensics, and others.
The newborn screening segment is expected to grow at a rapid pace in the coming years, owing to the factors such as rising incidences of blood disorders among newborn babies as well as the availability of high-precision and low-cost screening devices. Moreover, other factors such as reduced biohazard risks, short diagnosis period, easy collection & storage, and minimally invasive procedures amongst other blood collection techniques are key factors boosting the segment growth.
The therapeutic drug monitoring segment is estimated to account for a major share of the market during the forecast period, due to factors such as home or remote non-contagious sampling that make DBS an advantageous solution for therapeutic drug monitoring.
On the basis of type, the market is segmented into Whatman 903, Ahlstrom 226, FTA, and others. The Whatman 903 segment held a significant revenue share of the market and is projected to expand at a considerable CAGR during the projected period as it provides easy sampling, identification, transport, and collection of dried blood cards.
The Ahlstrom 226 segment is estimated to register lucrative growth in the coming years, owing to the high accuracy of the test results, easy diagnosis, collection, decreased material use and wastage, better reproducibility, and transport. Due to these factors, the demand for NBS with Ahlstrom 226 has been rising significantly, which is expected to exhibit promising growth in the segment during the forecast period.
The FTA segment is projected to hold a major market share in the coming years, due to the wide applications of FTA cards in DNA amplification and offering a short testing duration. It normally takes five to 30 minutes for sample analysis and to amplify the sample besides offering convenient, fast, and gives accurate results, which act as a pillar for the segment growth. An FTA Classic Card developed by Qiagen has a varied range of applications such as transgenic identification, plasmid screening, food & agriculture testing, STR analysis, whole genome amplification, genomics, forensics, drug discovery, and molecular biology among others.
In terms of region, the global dried blood spot collection cards market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period, due to the early adoption of advanced technology for screening devices. Moreover, factors such as mandatory use of newborn screening for newborns in the U.S. and Canada, well-developed medical infrastructure, and a rising number of blood disorder cases among babies are driving the regional market growth.
The US government has been working on the NBS development since 2016, as per a report by the National Institute of Children’s Health Quality. The report further stated that NBS was routinely performed on more than 4.5 million infants in the U.S., with a 99.9% or higher rate of participation. This led to the establishment of several collaborations to expedite improved newborn screening testing facilities in the country.
Europe is projected to exhibit a healthy CAGR during the forecast period, due to the increasing number of infectious disorders such as hepatitis B. In 2017, the European Centre for Disease Prevention and Control estimated that almost 26,900 persons were diagnosed with hepatitis B, at a prevalence rate of 7 cases per 100,000 individuals. With such a high number of cases, DBS is being used as a technique for early diagnosis and a better alternative than conventional blood sampling, which are likely to expand the market growth in the region.
Middle East & Africa is anticipated to register a substantial growth rate in the coming years, due to rising demand for blood sampling techniques for various disease detection. The introduction of many screenings or collection equipment that are less costly and affordable to small and poor nations presents a key driving factor for the market expansion in the region. DBS is a cost-effective technique and is easy to conduct, which helps boost market growth in underdeveloped as well as developing nations.
Segments
The global dried blood spot collection cards market has been segmented on the basis of
Application
- Infectious Disease Testing
- Newborn Screening
- Therapeutic Drug Monitoring
- Forensics
- Others
Type
- Whatman 903
- Ahlstrom 226
- FTA
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Ahlstrom
- QIAGEN
- PerkinElmer Inc.
- F. Hoffmann-La Roche Ltd
- CENTOGENE N.V.
- Shimadzu Scientific Instruments.
- Eastern Business Forms, Inc
- Pall Corporation.
- ARCHIMED Life Science GmbH
- Hemaxis
Competitive Landscape
Key players competing in the global dried blood spot collection cards market are Ahlstrom; QIAGEN; PerkinElmer Inc.; F. Hoffmann-La Roche Ltd; CENTOGENE N.V.; Shimadzu Scientific Instruments.; Eastern Business Forms, Inc; Pall Corporation.; ARCHIMED Life Science GmbH; and Hemaxis.
These companies adopted development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production expansion to expand their consumer base worldwide.
- In July 2020, PerkinElmer, Inc. launched a dry blood spot (DBS) based test for SARS-CoV-2 lgG using its GSP/DELFIA platform, enabling processing of up to 5,000 samples per day.
Request For Customization
Enquiry Before Buying
Speak With Analyst
